Main Menu

Success stories

Research at The Institute of Cancer Research, The Royal Marsden, and at Imperial College London and University College London, has already led to major improvements in treatment for men with prostate cancer. Find out about some of these advances below.


Abiraterone was discovered by the ICR in what is now the Cancer Research UK Cancer Therapeutics Unit.

Find out more


Researchers at the ICR were the first to show that cabazitaxel is effective for treating men with advanced castration-resistant prostate cancer (CRPC) after docetaxel and novel endocrine therapies have stopped working.

Find out more


Researchers at the ICR and The Royal Marsden have shown that the prostate cancer drug enzalutamide can improve overall survival of men regardless of the severity of their disease.

Find out more


Treatment with radioactive radium-223 gave men with late-stage prostate cancer longer overall survival and a better quality of life.

Find out more


Professor Johann de Bono's group led on the development of this PARP inhibitor, an anticancer drug that is now approved for the treatment of ovarian cancer.

Find out more